Clinical Trial: Centralized Pan-Middle East Survey on the Under-treatment of Hypercholesterolemia, Sub-study for the Gulf States

Study Status: Completed
Recruit Status: Completed
Study Type: Observational

Official Title: Centralized Gulf States Survey on the Undertreatment of Hypercholesterolemia

Brief Summary:

The purpose of the study is to establish the proportion of patients on lipid-lowering pharmacological treatment reaching the LDL-C goals according to the NCEP ATP III/updated 2004 NCEP ATP III guidelines, overall and by country, to establish the proportion of patients on lipid-lowering pharmacological treatment reaching the LDL-C goals according to the NCEP ATP III/updated 2004 NCEP ATP III in the following sub-populations:

  • Primary/secondary prevention patients.

  • Patients with metabolic syndrome (according to NCEP III definition). And to establish the proportion of patients on lipid-lowering pharmacological treatment reaching the LDL-C goals according to the Third Joint European Task Force guidelines/national guidelines, in the survey population and in the following sub-populations:

    • Primary/secondary prevention patients.
    • Patients with metabolic syndrome.

Detailed Summary:
Sponsor: AstraZeneca

Current Primary Outcome: To establish the proportion of patients on lipid-lowering pharmacological treatment reaching the LDL-C goals according to the NCEP ATP III/updated 2004 NCEP ATP III guidelines, overall and by country. [ Time Frame: 6 months- One visit only, no follow up visits. ]

Original Primary Outcome: Same as current

Current Secondary Outcome:

  • Proportion patients on lipid-lowering drugs (LLD) reaching the LDL-C goals according to the NCEP ATP III/ updated 2004 NCEP ATP III in subgroups: Primary/secondary prevention patients; Patients with metabolic syndrome ( NCEP III). [ Time Frame: 6 months- One visit only, no follow up visits. ]
  • Proportion patients on LLD reaching the LDL-C goals according to the Third Joint European Task Force guidelines/national guidelines, in the survey population and in sub-populations: Primary/secondary prevention patients; Patients with metabolic syndrome. [ Time Frame: 6 months- One visit only, no follow up visits. ]
  • To identify determinants (e.g. patient and physician characteristics, country-specific guidelines or recommendations) for undertreatment of hypercholesterolemia. [ Time Frame: 6 months- One visit only, no follow up visits. ]


Original Secondary Outcome:

  • The proportion of patients reaching the LDL-C goals according to the NCEP ATP III/updated 2004 NCEP ATP III in the following sub-populations: primary/secondary prevention patients, and patients with metabolic syndrome (according to NCEP III definition) [ Time Frame: 6 months- One visit only, no follow up visits. ]
  • The proportion of patients reaching the LDL-C goals according to the Third Joint European Task Force guidelines/national guidelines, in the following sub-populations: primary/secondary prevention patients, and patients with metabolic syndrome. [ Time Frame: 6 months- One visit only, no follow up visits. ]
  • To identify determinants (e.g. patient and physician characteristics, country-specific guidelines or recommendations) for undertreatment of hypercholesterolemia. [ Time Frame: 6 months- One visit only, no follow up visits. ]


Information By: AstraZeneca

Dates:
Date Received: December 11, 2009
Date Started: November 2009
Date Completion:
Last Updated: May 24, 2011
Last Verified: May 2011